Morgan Stanley stays overweight on Lupin post drug launch; sees up to 35% upside in 12 months News News / News 6 years ago 443 Views comments Morgan Stanley has put out a target price of Rs 1472 which translates into an upside of 35 percent from current levels. Read more
News Privacy a fundamental right subject to reasonable restrictions: Government News / News - 6 years ago
News Spl CBI Director Rakesh Asthana moves SC against Centre#39;s decision to divest him of duties News / News - 5 years ago
Comments